Potentially Resectable Hepatocellular Carcinoma Clinical Trials in Harbin, Heilongjiang

Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)